OpGen Inc. Faces Delisting Concerns

TL;DR

OpGen might get delisted, check their listing status ASAP.

AI Summary

OpGen, Inc. filed an 8-K on December 27, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The filing indicates a potential transfer of listing, with the earliest event reported on December 19, 2024. The company is incorporated in Delaware and its principal executive offices are located in Clarksburg, MD.

Why It Matters

This filing signals potential issues with OpGen's continued listing on an exchange, which could impact its stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.

Key Players & Entities

• OpGen, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• Clarksburg, MD (location) — Principal executive offices
• 20871 (zip_code) — Zip code for principal executive offices
• 240-813-1260 (phone_number) — Registrant's telephone number
• December 19, 2024 (date) — Date of earliest event reported
• December 27, 2024 (date) — Date of report

FAQ

Filing Documents

• opgeninc_8k.htm (8-K) — 29KB
• 0001829126-24-008575.txt ( ) — 198KB
• opgn-20241219.xsd (EX-101.SCH) — 3KB
• opgn-20241219_lab.xml (EX-101.LAB) — 33KB
• opgn-20241219_pre.xml (EX-101.PRE) — 22KB
• opgeninc_8k_htm.xml (XML) — 4KB

01 Notice of Delisting or Failure to

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 19, 2024, despite OpGen, Inc. (the "Company") regaining short-term compliance with the minimum stockholders' equity requirement of the Nasdaq Capital Market ("Nasdaq") pursuant to Nasdaq Listing Rule 5550(b)(1) after the deadline for such compliance granted to the Company prior to AEI Capital Ltd. acquiring a controlling interest in the Company, the Nasdaq Listing and Hearing Review Council (the "Listing Council") affirmed the decision of the Nasdaq Hearings Panel (the "Panel"). As previously disclosed, on August 16, 2024, the Company received written notice of the Panel's determination to effect a trading suspension and delisting of the Company's securities based upon the Company's continued non-compliance with the minimum stockholders' equity requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Rule"). While the trading suspension was effective as of August 20, 2024, the Company had appealed the Panel's decision to the Listing Council. Although the Company continues to disagree with the Listing Council's decision, as a result of such decision, unless Nasdaq's Board of Directors determines to review such decision pursuant to Nasdaq Listing Rule 5825, Nasdaq will ultimately file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission (the "Commission") that will remove the Company's securities from listing on Nasdaq. The filing of the Form 25 had been stayed pending the Company's appeal of the Panel's decision to the Listing Council. The Company's shares of common stock will continue trading on the OTC Markets under the symbol "OPGN" following the filing of the Form 25 with the Commission. Consistent with the Listing Council's decision, the Listing Council welcomes the Company's application for relisting and the Company plans to apply for relisting with

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking harbor from liability established thereunder. Such forward-looking statements are subject to risks and uncertainties that are often difficult to predict, are beyond the Company's control, and which may cause results to differ materially from expectations, including the risk that the Company may not be able to relist its securities on Nasdaq. In addition, for a further discussion of factors that could materially affect the outcome of the Company's forward-looking statements and its future results and financial condition, see "Risk Factors" in Part I, Item 1A, of the Company's Annual Report on Form 10-K for the year ended December 31, 2023 and its other reports filed with the Securities and Exchange Commission. The Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: December 26, 2024 OpGen, Inc. By: /s/ John Tan Honjian Name: John Tan Honjian Title: Chairman and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR